{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:00:00Z","timestamp":1773025200194,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1124\/jpet.113.212654","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T07:14:35Z","timestamp":1400224475000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Repurposing Miltefosine for the Treatment of Immune-Mediated Disease?"],"prefix":"10.1016","volume":"350","author":[{"given":"Auke P.","family":"Verhaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon E.","family":"Wildenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maikel P.","family":"Peppelenbosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Hommes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gijs R.","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.113.212654_bib1","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1124\/jpet.113.212654_bib2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.trstmh.2008.05.015","article-title":"Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis","volume":"102","author":"Ansari","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1124\/jpet.113.212654_bib3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1074\/jbc.273.4.2169","article-title":"Apoptosis triggered by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine is prevented by increased expression of CTP:phosphocholine cytidylyltransferase","volume":"273","author":"Baburina","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.113.212654_bib4","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.ejmech.2010.01.061","article-title":"Computational screening for membrane-directed inhibitors of mast cell activation","volume":"45","author":"Batista","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1124\/jpet.113.212654_bib5","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.ejmech.2011.02.068","article-title":"Lipid-like sulfoxides and amine oxides as inhibitors of mast cell activation","volume":"46","author":"Batista","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1124\/jpet.113.212654_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2009.11.018","article-title":"The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models","volume":"628","author":"B\u00e4umer","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.113.212654_bib7","first-page":"238","article-title":"Daily oral miltefosine (hexadecyl-phosphocholine) in patients with advanced non-small-cell lung-cancer - a phase-II study","volume":"15","author":"Berdel","year":"1992","journal-title":"Onkologie"},{"key":"10.1124\/jpet.113.212654_bib8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/0192623309344088","article-title":"Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys","volume":"37","author":"Bianciardi","year":"2009","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.113.212654_bib9","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1074\/jbc.270.19.11612","article-title":"Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine","volume":"270","author":"Boggs","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.113.212654_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1515\/znb-1964-1207","article-title":"[Increase in the phagocytosis of peritoneal macrophages by lysolecithin]","volume":"19","author":"Burdzy","year":"1964","journal-title":"Z Naturforsch B"},{"key":"10.1124\/jpet.113.212654_bib11","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.4049\/jimmunol.175.5.3214","article-title":"Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts","volume":"175","author":"Chakraborty","year":"2005","journal-title":"J Immunol"},{"key":"10.1124\/jpet.113.212654_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/jpet.113.212654_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0169-4758(86)90157-2","article-title":"In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis","volume":"2","author":"Croft","year":"1986","journal-title":"Parasitol Today"},{"key":"10.1124\/jpet.113.212654_bib14","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","article-title":"The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani","volume":"36","author":"Croft","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.113.212654_bib15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","article-title":"Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours","volume":"38","author":"Crul","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.113.212654_bib16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1398-9995.2010.02341.x","article-title":"Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis","volume":"65","author":"D\u00f6lle","year":"2010","journal-title":"Allergy"},{"key":"10.1124\/jpet.113.212654_bib17","first-page":"E115","article-title":"A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma","volume":"93","author":"Dumontet","year":"2006","journal-title":"Bull Cancer"},{"key":"10.1124\/jpet.113.212654_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0305-7372(90)90053-I","article-title":"Hexadecylphosphocholine: a new and selective antitumor drug","volume":"17","author":"Eibl","year":"1990","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/jpet.113.212654_bib19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF01225687","article-title":"Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells","volume":"121","author":"Eue","year":"1995","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1124\/jpet.113.212654_bib20","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/jac\/dkt262","article-title":"Immunomodulatory effects of antileishmanial drugs","volume":"68","author":"Ghosh","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/jpet.113.212654_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0162-3109(90)90017-9","article-title":"The influence of ether lipid (AMG) on histamine release from isolated rat mast cells: synergistic interaction with TPA indicates protein kinase C activation","volume":"20","author":"Grosman","year":"1990","journal-title":"Immunopharmacology"},{"key":"10.1124\/jpet.113.212654_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2133.2009.09434.x","article-title":"Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Hartmann","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1124\/jpet.113.212654_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1586\/eci.10.32","article-title":"Crohn\u2019s disease as an immunodeficiency","volume":"6","author":"Hayee","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1124\/jpet.113.212654_bib24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.113.212654_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1476-511X-9-33","article-title":"Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids","volume":"9","author":"Jim\u00e9nez-L\u00f3pez","year":"2010","journal-title":"Lipids Health Dis"},{"key":"10.1124\/jpet.113.212654_bib26","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1016\/j.febslet.2008.10.006","article-title":"Lipid rafts and T-lymphocyte function: implications for autoimmunity","volume":"582","author":"Kabouridis","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.113.212654_bib27","first-page":"1093","article-title":"Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation","volume":"2","author":"Kondapaka","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.113.212654_bib28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.36.8.1630","article-title":"Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice","volume":"36","author":"Kuhlencord","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.113.212654_bib29","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2001.19.21.4150","article-title":"Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer","volume":"19","author":"Leonard","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.113.212654_bib30","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1111\/j.1468-3083.2012.04689.x","article-title":"Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria","volume":"27","author":"Magerl","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1124\/jpet.113.212654_bib31","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(06)68265-2","article-title":"Defective acute inflammation in Crohn\u2019s disease: a clinical investigation","volume":"367","author":"Marks","year":"2006","journal-title":"Lancet"},{"key":"10.1124\/jpet.113.212654_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11745-007-3026-8","article-title":"Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process","volume":"42","author":"M\u00e9nez","year":"2007","journal-title":"Lipids"},{"key":"10.1124\/jpet.113.212654_bib33","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/infdis\/jir551","article-title":"Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis","volume":"204","author":"Mukhopadhyay","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1124\/jpet.113.212654_bib34","first-page":"174","article-title":"Lysolecithin analogs: a new class of immunopotentiators with antitumor activity","volume":"17","author":"Munder","year":"1976","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1124\/jpet.113.212654_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01891668","article-title":"Lysophosphatidylcholine (lysolecithin) and its synthetic analogs. Immune-modulating and other biologic effects","volume":"2","author":"Munder","year":"1979","journal-title":"Springer Semin Immunopathol"},{"key":"10.1124\/jpet.113.212654_bib36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0959-8049(05)80142-X","article-title":"Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer","volume":"29A","author":"Planting","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.113.212654_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.intimp.2012.03.016","article-title":"Miltefosine enhances phagocytosis but decreases nitric oxide production by peritoneal macrophages of C57BL\/6 mice","volume":"13","author":"Ponte","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"10.1124\/jpet.113.212654_bib38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbamem.2004.01.010","article-title":"Hexadecylphosphocholine interaction with lipid monolayers","volume":"1661","author":"Rakotomanga","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.113.212654_bib39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/BF02535557","article-title":"Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats","volume":"22","author":"Scherf","year":"1987","journal-title":"Lipids"},{"key":"10.1124\/jpet.113.212654_bib40","first-page":"752906","article-title":"Lipid rafts in mast cell biology","volume":"2011","author":"Silveira","year":"2011","journal-title":"J Lipids"},{"issue":"Suppl 1","key":"10.1124\/jpet.113.212654_bib41","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1124\/jpet.113.212654_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","article-title":"The activation of Akt\/PKB signaling pathway and cell survival","volume":"9","author":"Song","year":"2005","journal-title":"J Cell Mol Med"},{"key":"10.1124\/jpet.113.212654_bib43","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.113.212654_bib44","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"10.1124\/jpet.113.212654_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1124\/jpet.113.212654_bib46","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gutjnl-2012-303956","article-title":"Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease","volume":"62","author":"Uhlig","year":"2013","journal-title":"Gut"},{"key":"10.1124\/jpet.113.212654_bib47","first-page":"260","article-title":"Daily oral miltefosine (hexadecylphosphocholine) in patients with advanced breast cancer: a phase II study","volume":"16","author":"Unger","year":"1993","journal-title":"Onkologie"},{"key":"10.1124\/jpet.113.212654_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/02841868909111249","article-title":"Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo","volume":"28","author":"Unger","year":"1989","journal-title":"Acta Oncol"},{"key":"10.1124\/jpet.113.212654_bib49","doi-asserted-by":"crossref","first-page":"39541","DOI":"10.1074\/jbc.M203176200","article-title":"Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis","volume":"277","author":"van der Luit","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.113.212654_bib50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1042\/bj20030179","article-title":"Different modes of internalization of apoptotic alkyl-lysophospholipid and cell-rescuing lysophosphatidylcholine","volume":"374","author":"van der Luit","year":"2003","journal-title":"Biochem J"},{"key":"10.1124\/jpet.113.212654_bib51","first-page":"1974","article-title":"Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease","volume":"19","author":"Verhaar","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1124\/jpet.113.212654_bib52","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0959-8049(05)80369-7","article-title":"Phase II study of oral miltefosine in patients with squamous cell head and neck cancer","volume":"29A","author":"Verweij","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.113.212654_bib53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0959-8049(93)90177-H","article-title":"Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult\u2014an EORTC Soft Tissue and Bone Sarcoma Group Study","volume":"29A","author":"Verweij","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.113.212654_bib54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/BF01211805","article-title":"A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours","volume":"118","author":"Verweij","year":"1992","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1124\/jpet.113.212654_bib55","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/jid.2008.248","article-title":"Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo","volume":"129","author":"Weller","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.113.212654_bib56","doi-asserted-by":"crossref","first-page":"11025","DOI":"10.1074\/jbc.273.18.11025","article-title":"Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine","volume":"273","author":"Wieder","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.113.212654_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01202215","article-title":"Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro","volume":"121","author":"Zeisig","year":"1995","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652418737X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652418737X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.113.212654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:43:19Z","timestamp":1739986999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652418737X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S002235652418737X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.113.212654","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing Miltefosine for the Treatment of Immune-Mediated Disease?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.113.212654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}